# UCB

> UCB is a publicly listed Belgian biopharmaceutical company focused on severe neurological and immune-system diseases. It discovers, develops, manufactures and commercializes specialist medicines, with a portfolio led by BIMZELX, RYSTIGGO, ZILBRYSQ, FINTEPLA and EVENITY, while also providing patient-support programs and investing in new modalities such as cell therapy and T-cell engagers. UCB generated EUR 7.741 billion in 2025 revenue, spent 24% of revenue on R&D and reached more than 3.1 million patients.

- **Founded:** 1928
- **Headquarters:** Brussels, Belgium
- **Founders:** Emmanuel Janssen (Founder)
- **Team size:** More than 9,000 employees across approximately 40 countries
- **Products:** BIMZELX (bimekizumab), CIMZIA (certolizumab pegol), BRIVIACT (brivaracetam), FINTEPLA (fenfluramine), RYSTIGGO (rozanolixizumab)
- **Notable:** Reached more than 3.1 million patients in 2025., Grew 2025 revenue 26% to EUR 7.741 billion and adjusted EBITDA 79% to EUR 2.636 billion., Five growth medicines more than doubled combined net sales to over EUR 3.3 billion in 2025.

## Products & services

- **BIMZELX (bimekizumab)** — Biologic inhibiting IL-17A and IL-17F for plaque psoriasis, psoriatic arthritis, axial spondyloarthritis and hidradenitis suppurativa.
- **CIMZIA (certolizumab pegol)** — Biologic for multiple inflammatory diseases including rheumatoid and psoriatic arthritis, Crohn's disease and axial spondyloarthritis.
- **BRIVIACT (brivaracetam)** — Prescription treatment for epilepsy.
- **FINTEPLA (fenfluramine)** — Treatment for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome.
- **RYSTIGGO (rozanolixizumab)** — FcRn-targeted treatment for generalized myasthenia gravis, with self-administration options approved in some markets.
- **ZILBRYSQ (zilucoplan)** — Once-daily subcutaneous C5 complement inhibitor for generalized myasthenia gravis.
- **EVENITY (romosozumab)** — Sclerostin inhibitor for osteoporosis, commercialized globally with Amgen and Astellas.
- **KYGEVVI (doxecitine and doxribtimine)** — The first FDA-approved treatment for adults and children with thymidine kinase 2 deficiency.
- **UCBCares** — Personalized information and support for people using UCB medicines and for healthcare professionals.

## Achievements

- Reached more than 3.1 million patients in 2025.
- Grew 2025 revenue 26% to EUR 7.741 billion and adjusted EBITDA 79% to EUR 2.636 billion.
- Five growth medicines more than doubled combined net sales to over EUR 3.3 billion in 2025.
- BIMZELX reached more than 116,000 patients and EUR 2.2 billion in 2025 sales.
- Won U.S. approval for KYGEVVI in 2025 as the first treatment for TK2 deficiency.
- Earned a place on CDP's Climate A List and ranked second in Sustainalytics' global biotechnology sector in 2025.
- Completed the transformation from a diversified chemicals and films group into a focused biopharmaceutical company.

## Latest updates

- **2026-07** — Presented new data from its targeted generalized myasthenia gravis portfolio at the International Congress on Neuromuscular Diseases.
- **2026-06** — Completed the acquisition of Candid Therapeutics for up to $2.2 billion, adding the investigational BCMA-directed T-cell engager cizutamig and related programs.
- **2026-04** — Agreed to acquire Neurona Therapeutics for up to $1.15 billion, adding investigational neuronal cell therapy NRTX-1001 for drug-resistant temporal lobe epilepsy; closing status was not confirmed in the reviewed public materials.
- **2026-03** — Selected Gwinnett County, Georgia, for a planned 460,000-square-foot biologics manufacturing facility expected to support about 330 permanent jobs.
- **2026-02** — Reported 2025 revenue of EUR 7.741 billion, up 26%, and more than 3.1 million patients reached.
- **2025-11** — The FDA approved KYGEVVI for adults and children with genetically confirmed TK2 deficiency.

## Links

- Website: https://www.ucb.com
- LinkedIn: https://www.linkedin.com/company/ucb-pharma
- Twitter/X: https://www.twitter.com/ucb_news
- YouTube: https://www.youtube.com/UCB
- Instagram: https://www.instagram.com/ucbglobal
- Facebook: https://www.facebook.com/ucbglobal

---

Profile page: https://yespress.io/ucb
Published by YesPress — https://yespress.io
Last updated: 2026-08-11